Today
-0.85%
5 Days
+0.36%
1 Month
+1.70%
6 Months
+6.90%
Year to Date
+23.31%
1 Year
+10.55%
• Philip Morris USA announced a strategic contract manufacturing arrangement with PMI affiliates. • Institutional capital inflows were driven by high dividend yields and resilient cash flow. • Altria reported annual revenue of $20.14B and a net profit of $6.93B.
• Profit-taking and margin concerns caused downward price pressure on Anheuser-Busch InBev. • Volume weakness in key Asian markets hindered a unified global volume recovery. • The stock's RSI stands at 41.859 and Williams %R indicates oversold conditions.
• FDA discourse regarding potential nicotine caps creates significant regulatory uncertainty for Altria. • Rising Treasury yields reduce the attractiveness of Altria’s dividend relative to fixed-income investments. • Competitive pressure in smoke-free segments and persistent inflation dampen investor confidence in growth.
• Philip Morris shares declined on growth margin concerns and nicotine product regulatory headwinds. • Strengthening U.S. dollar and potential European excise taxes create significant earnings translation risks. • Investors are prioritizing near-term margin stability over the company's long-term smoke-free strategic transition.
• Altria Group stock declined amid insider selling and analyst concerns. • Directors sold shares, potentially signaling reduced internal confidence. • Analyst price targets suggest limited upside or potential downside.
• Ambev reported strong organic net revenue and EBITDA growth. • Operating cash flow reached a decade-high for the first quarter. • Company reinforced shareholder returns via capital payments and buybacks.


| Shareholders | Proportion |
|---|---|
| Vanguard Capital Management, LLC | 6.52% |
| BlackRock Institutional Trust Company, N.A. | 5.57% |
| State Street Investment Management (US) | 4.36% |
| Charles Schwab Investment Management, Inc. | 3.92% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 39.05% |
| Investment Advisor/Hedge Fund | 17.61% |
| Research Firm | 2.66% |
| Bank and Trust | 1.52% |
Related Instruments
Popular Instruments